These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
652 related articles for article (PubMed ID: 22675168)
1. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Wentzensen N; Schwartz L; Zuna RE; Smith K; Mathews C; Gold MA; Allen RA; Zhang R; Dunn ST; Walker JL; Schiffman M Clin Cancer Res; 2012 Aug; 18(15):4154-62. PubMed ID: 22675168 [TBL] [Abstract][Full Text] [Related]
2. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial. Wright TC; Behrens CM; Ranger-Moore J; Rehm S; Sharma A; Stoler MH; Ridder R Gynecol Oncol; 2017 Jan; 144(1):51-56. PubMed ID: 28094038 [TBL] [Abstract][Full Text] [Related]
3. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study. El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL; Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481 [TBL] [Abstract][Full Text] [Related]
4. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data. Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358 [TBL] [Abstract][Full Text] [Related]
5. p16/Ki-67 dual staining has a better accuracy than human papillomavirus (HPV) testing in women with abnormal cytology under 30 years old. Pirtea L; Secosan C; Margan M; Moleriu L; Balint O; Grigoras D; Sas I; Horhat F; Jianu A; Ilina R Bosn J Basic Med Sci; 2019 Nov; 19(4):336-341. PubMed ID: 29924960 [TBL] [Abstract][Full Text] [Related]
6. Triage of LSIL/ASC-US with p16/Ki-67 dual staining and human papillomavirus testing: a 2-year prospective study. White C; Bakhiet S; Bates M; Keegan H; Pilkington L; Ruttle C; Sharp L; O' Toole S; Fitzpatrick M; Flannelly G; O' Leary JJ; Martin CM Cytopathology; 2016 Aug; 27(4):269-76. PubMed ID: 26932360 [TBL] [Abstract][Full Text] [Related]
7. Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening. Cuzick J; Adcock R; Carozzi F; Gillio-Tos A; De Marco L; Del Mistro A; Frayle H; Girlando S; Sani C; Confortini M; Zorzi M; Giorgi-Rossi P; Rizzolo R; Ronco G; Int J Cancer; 2020 Oct; 147(7):1864-1873. PubMed ID: 32170961 [TBL] [Abstract][Full Text] [Related]
8. p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population. Luttmer R; Dijkstra MG; Snijders PJ; Berkhof J; van Kemenade FJ; Rozendaal L; Helmerhorst TJ; Verheijen RH; Ter Harmsel WA; van Baal WM; Graziosi PG; Quint WG; Spruijt JW; van Dijken DK; Heideman DA; Meijer CJ Mod Pathol; 2016 Aug; 29(8):870-8. PubMed ID: 27150161 [TBL] [Abstract][Full Text] [Related]
9. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program. Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891 [TBL] [Abstract][Full Text] [Related]
10. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084 [TBL] [Abstract][Full Text] [Related]
11. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. Ikenberg H; Bergeron C; Schmidt D; Griesser H; Alameda F; Angeloni C; Bogers J; Dachez R; Denton K; Hariri J; Keller T; von Knebel Doeberitz M; Neumann HH; Puig-Tintore LM; Sideri M; Rehm S; Ridder R; J Natl Cancer Inst; 2013 Oct; 105(20):1550-7. PubMed ID: 24096620 [TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. Bergeron C; Ikenberg H; Sideri M; Denton K; Bogers J; Schmidt D; Alameda F; Keller T; Rehm S; Ridder R; Cancer Cytopathol; 2015 Jun; 123(6):373-81. PubMed ID: 25891096 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China. Yu LL; Chen W; Lei XQ; Qin Y; Wu ZN; Pan QJ; Zhang X; Chang BF; Zhang SK; Guo HQ; Qiao YL Oncotarget; 2016 Apr; 7(16):21181-9. PubMed ID: 27029033 [TBL] [Abstract][Full Text] [Related]
14. [Clinical value of p16 Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350 [No Abstract] [Full Text] [Related]
15. Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women. Ebisch RM; van der Horst J; Hermsen M; Rijstenberg LL; Vedder JE; Bulten J; Bosgraaf RP; Verhoef VM; Heideman DA; Snijders PJ; Meijer CJ; van Kemenade FJ; Massuger LF; Melchers WJ; Bekkers RL; Siebers AG Mod Pathol; 2017 Jul; 30(7):1021-1031. PubMed ID: 28304400 [TBL] [Abstract][Full Text] [Related]
16. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women. Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224 [TBL] [Abstract][Full Text] [Related]
17. Expression of p16/Ki-67 in ASC-US/LSIL or Normal Cytology with Presence of Oncogenic HPV DNA. Solares C; Velasco J; Álvarez-Ruiz E; González-Fernández L; Encinas AI; Astudillo A; Schneider J Anticancer Res; 2015 Nov; 35(11):6291-5. PubMed ID: 26504065 [TBL] [Abstract][Full Text] [Related]
18. Sensitivity and specificity values of high-risk HPV DNA, p16/ki-67 and HPV mRNA in young women with atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL). Frega A; Pavone M; Sesti F; Leone C; Bianchi P; Cozza G; Colombrino C; Lukic A; Marziani R; De Sanctis L; Delli Carpini G; Caserta D; Ciavattini A Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10672-10677. PubMed ID: 31858534 [TBL] [Abstract][Full Text] [Related]
19. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women. Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982 [TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology. Peeters E; Wentzensen N; Bergeron C; Arbyn M Cancer Cytopathol; 2019 Mar; 127(3):169-180. PubMed ID: 30811902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]